• Product Description:

Tranbit (Tenofovir alafenamide fumarate) is a phosphonamidate prodrug of tenofovir (2′-deoxyadenosine monophosphate analog). Tenofovir alafenamide as a lipophilic cell-permeant compound enters primary hepatocytes by passive diffusion and by the hepatic uptake transporters OATP1B1 and OATP1B3. Tenofovir alafenamide is then converted to tenofovir through hydrolysis primarily by carboxylesterase 1 (CES1) in primary hepatocytes. Intracellular tenofovir is subsequently phosphorylated by cellular kinases to the pharmacologically active metabolite tenofovir diphosphate. Tenofovir diphosphate inhibits HBV replication through incorporation into viral DNA by the HBV reverse transcriptase, which results in DNA chain-termination.

Tenofovir diphosphate is a weak inhibitor of mammalian DNA polymerases that include mitochondrial DNA polymerase γ and there is no evidence of toxicity to mitochondria in cell culture.

  • Product Features:

Product Name Tranbit
Generic Name Tenofovir alafenamide fumarate INN 25 mg Tablet
FDA Approved Indications
  • Tranbit (Tenofovir alafenamide fumarate) is a hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor and indicated for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease.
Packaging Each Commercial box contains 3×10’s tablets in Alu- Alu blister pack.
Prescribing Information Tranbit 25mg (PDF)